NCT03802240View on ClinicalTrials.gov

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

PHASE3CompletedINTERVENTIONAL
Enrollment

492

Participants

Timeline

Start Date

July 11, 2019

Primary Completion Date

July 31, 2021

Study Completion Date

June 30, 2023

Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
DRUG

Sintilimab

200mg IV Q3W

DRUG

IBI305

15mg/kg IV Q3W

DRUG

Pemetrexed

500mg/m2 IV Q3W

DRUG

Cisplatin

75mg/m2 IV Q3W

DRUG

Placebo1

Placebo1 IV Q3W

DRUG

Placebo2

Placebo2 IV Q3W

Trial Locations (1)

200030

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT03802240 - Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure | Biotech Hunter | Biotech Hunter